ABSTRACT
Chemotherapy after surgery is one of the adjuvant therapy components in breast cancer patients. In the current study, Taxane-based and Anthracycline-based regimes were compared to Cyclophosphamide, Methotrexate and 5-Fluorouracil [CMF] chemotherapy after modified radical mastectomy [MRM] surgery in terms of disease-free survival [DFS]. Sixty-two patients with confirmed breast cancer that underwent MRM surgery at no metastasis stage [M0] enrolled. These patients were received one of the three types of adjuvant chemotherapies that mentioned above and the relapse/metastasis in 8-year follow-up was recorded. In addition, some paraclinical and demographical factors were recorded and the efficacy of the different chemotherapy regimes was compared using log-logistic survival model. The mean age [SD] of patients was 49 [1.31]. More than 40% of patients had tumors with grade 3. The median time of follow-up was 20.0 months and the rate of 5-year DFS was 48%. Survival analysis indicated that type of chemotherapy [OR [Taxane/CMF] =3.676; OR [Anthracycline/CMF]=3.185], histological grade [OR=2.528], tumor size [OR=5.598] and number of lymph nodes [OR=1.112] affect the DFS. The results of the current study indicated that the efficacy of Taxane-based and Anthracycline-based is more than CMF. This study also showed that early detection of tumor was an important factor for a successful treatment in terms of DFS, and so, it declares the roll of screening and public education